|
|
FIFTH INTERNATIONAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM
Getting to a High Integrity Future Sustainably
|
May 3 - 5, 2011
Renaissance Polat Istanbul Hotel
Istanbul, Turkey
|
|
KEYNOTE SPEAKER
|
David Brennan
Chief Executive Officer, AstraZeneca, President, International Federation of Pharmaceutical, Manufacturers and Associations (IFPMA), Past Chairman, Pharmaceutical Research and Manufacturers of America (PhRMA), London, UK
|
|
|
|
|
PHARMA COMPLIANCE TRACKS
|
- European Union Compliance Update
- Central and Eastern Europe Compliance Update
- Middle East and Africa Compliance Update
- FCPA and Global Anticorruption
|
- Global Compliance Audits and Monitoring
- Global Transparency, Discourse and Aggregate Spend
- Global Compliance Case Studies
|
|
OTHER KEYNOTE FACULTY
|
Philippa Foster Back, OBE
Director, Institute of Business Ethics, Chairman, UK Antarctic Heritage Trust, Past President, Association of Corporate Treasurers, London, UK |
Bulent Becan
Managing Partner, Atuva Management Consultancy and Trade Ltd., Consultant in Ethics Issues, Turkish Research Based Pharmaceutical Companies Association (AIFD), Istanbul, Turkey |
Joe Henein
President and Chief Executive Officer, NewBridge Pharmaceuticals, Former Regional Managing Director, Middle East & North Africa, Wyeth Pharmaceuticals, Dubai, United Arab Emirates
|
Jose F. Zamarriego Izquierdo
Director Unidad de Supervision Deontologica, FARMAINDUSTRIA, Madrid, Spain |
Philippe Montigny
Certification Committee President, ETHIC Intelligence International, President, ETHIC Intelligence France, Executive Director and Partner, International Development & Strategies - France, Paris, France |
Chrisoula Nikidis
Director, Ethics and Compliance, Canada's Research-Based Pharmaceutical Companies (Rx&D), Ottawa, ON, Canada
|
Marie-Claire Pickaert
Deputy Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium |
Mark Pieth, PhD
Professor of Criminal Law, Basel University, Chairman, Working Group on Bribery in International Business Transactions, Organization for Economic Co-operation and Development (OECD), Member, Swiss Federal Gaming Commission, Board Chairman, Basel Institute on Governance, Basel, Switzerland
|
Vladimir Shipkov
Chief Executive Officer, Association of International Pharmaceutical Manufacturers, Member, IFPMA Council, Former Head, Ministry of Health Pharmaceutical Inspectorate, Former Deputy Chief, Federal Service for Intellectual Property, Patents and Trademarks (Rospatent), Moscow, Russian Federation |
Heather Simmonds
Director and Chair, Code of Practice Panel, Prescription Medicines Code of Practice Authority, London, UK
|
|
|
|
SPECIAL SESSIONS ON EUROPEAN UNION COMPLIANCE ISSUES BY:
|
Ted Acosta, Esq.
Principal, Ernst & Young LLP, Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France |
Pierre E. Dupourque
Regional Compliance Director, Corporate Compliance, International Investigations and Programs, Pfizer Inc, Mannheim, Germany |
Sylvia Fondaneche
Director, International Congresses & Events, sanofi-aventis, President, International Pharmaceutical, Congress Advisory Association (IPCAA), Paris, France
|
Gary F. Giampetruzzi, Esq.
Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc, New York, NY, USA |
Thomas Kellner, MD
Managing Partner, AXDEV Europe, Germany, Global Alliance for Medical Education, Munich, Germany |
Bernard Maillet, MD
Secretary General, European Union of Medical Specialties (UEMS) And European Accreditation Council for Continuing Medical Education (EACCME), Brussels, Belgium
|
Brian Riewerts
Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Baltimore, MD, USA |
Marco Sugarelli, Esq.
Legal Affairs Associate Director, Pfizer Italia, Rome, Italy |
Paul B. Woods, BPharm, MA, MRPharmS
Global Compliance Policy Director, AstraZeneca, Macclesfield, Cheshire, UK
|
|
|
SPECIAL SESSIONS ON CENTRAL AND EASTERN EUROPEAN
COMPLIANCE ISSUES BY:
|
Tomasz Kruk
Global Compliance Counsel, Actavis, Steinhausen, Switzerland |
Artur Nagapetyan
Country Compliance Officer, Novartis Pharma LLC, Moscow, Russian Federation
|
Martin Schloh, PhD
Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Munich, Germany |
Mariusz Witalis
Partner, Fraud Investigation and Dispute Services, Ernst & Young LLP, Warsaw, Poland
|
|
|
SPECIAL SESSIONS ON MIDDLE EAST/AFRICA COMPLIANCE ISSUES BY:
|
Nabil Daoud
Managing Director, MENA, Eli Lilly and Company, Chair, MEA LAWG Ethics Review Board, Beirut, Lebanon |
Nidal Fakhoury
Regional Managing Director - Middle East, MSD, Merck, Chairman, PhRMAG, Dubai, United Arab Emirates |
Sameh Farag
Regional Compliance Director, MEA, Merck, Dubai, United Arab Emirates
|
Liz MacGillivray
Head of Compliance AMAC Region (Asia Pacific, Middle East & African Countries), Novartis, Jumeirah Village, United Arab Emirates |
Kirti Narsai, MSc(Pharm), MBA
Head: Scientific and Regulatory Affairs, Pharmaceutical Industry Association of South Africa, Vorna Valley, South Africa |
Yasser A. Omar, LL.B.
Partner, Shalakany Law Firm, Dubai, United Arab Emirates
|
|
|
SPECIAL SESSIONS ON GLOBAL COMPLIANCE AUDITING AND MONITORING BY:
|
Bret A. Campbell, Esq.
Partner, Business Fraud and Complex Litigation Practice, Cadwalader, Wickersham & Taft LLP, Washington, DC, USA |
Peter Dieners, Esq.
Partner, Clifford Chance, Düsseldorf, Germany |
Patricia A. Etzold, CPA
Partner, PricewaterhouseCoopers LLP, New York, NY, USA
|
Barbara R. Giddings, RN, MHA, CHC
Global Commercial Compliance, Biogen Idec, Weston, MA, USA |
Ryan Murphy
Director, PricewaterhouseCoopers LLP, Chicago, IL, USA
|
|
|
SPECIAL SESSIONS ON FCPA AND ANTICORRUPTION BY:
|
John T. Bentivoglio, Esq.
Partner, Skadden Arps LLP, Former Special Counsel for Healthcare Fraud, and Chief Privacy Officer, Department of Justice, Washington, DC, USA |
Gary DiBianco, Esq.
Partner, Skadden Arps LLP, Former Trial Attorney, Criminal Division, Former Special Assistant US Attorney, Eastern District of Virginia, US Department of Justice, London, UK |
John Parsons
Associate Director, Head of EUMEA Legal and Compliance, BioMarin Europe Limited, London, UK
|
SanDee Priser
Partner, Fraud Investigation and Dispute Services, Ernst & Young LLP, Frankfurt am Main, Germany |
Michael Roberts, Esq.
Partner, Hogan Lovells International LLP, London, UK |
Jeffrey Rosenbaum
Global Head, Ethics and Compliance, Novartis Oncology, Florham Park, NJ, USA
|
Joseph B. Tompkins, Jr.
Partner, Sidley Austin LLP, Former Deputy Chief of the Fraud Section, Criminal Division of the United States Department of Justice, Washington, DC, USA |
John Wilson
Global Lead - AntiBribery and AntiCorruption Programme, AstraZeneca, London, UK
|
|
|
SPECIAL SESSIONS ON GLOBAL TRANSPARENCY, DISCLOSURE AND AGGREGATE SPEND ISSUES BY:
|
Ronny Arijs
Vice President Global Sustainability & Chief Compliance Officer, Grunenthal, Brussels, Belgium |
Bridget Bourgeois
Partner, Ernst & Young LLC, Atlanta, GA, USA |
William E. Buzzeo, MS
Vice President and General Manager - Global Compliance Solutions, Cegedim Relationship Management, Richmond, VA, USA
|
Michael K. Loucks, Esq.
Partner, Skadden Arps LLP, Former Acting United States Attorney, US Attorney's Office for the District of Massachusetts, Boston, MA, USA |
Guillaume Roussel
Vice President, Compliance Solutions EMEA, Cegedim, Paris, France
|
|
|
SPECIAL GLOBAL COMPLIANCE CASE STUDIES BY:
|
Sue Egan
Director and Principal Consultant, Sue Egan Associates, Former Vice President Compliance, AstraZeneca, London, UK |
Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA
|
Maxine Nogard
Senior Director, Global Corporate Compliance, Biogen Idec Inc., Weston, MA, USA
|
Elisabethann Wright, Esq.
Partner, Hogan Lovells, Former, Senior Legal Officer and Hearing Officer, EFTA Surveillance Authority, Brussels, Belgium
|
|
|
A SPECIAL REPORT FROM ASIA BY:
|
John Auerbach, MA
Partner, Fraud Investigation & Dispute Services, Ernst & Young China, Shanghai, China |
Yuet-Ming Tham, Esq.
Partner and Head, Regulatory, Compliance & Investigations Group, AsiaDLA Piper, Former Regional Compliance Director, Legal Division, Corporate Compliance, Pfizer Inc, Hong Kong
|
|
|
AND A SPECIAL SESSION ON THE FUTURE: ENVISIONING PHARMA COMPLIANCE IN 2015
|
Stephen F. Mohr, Esq.
Global Compliance Officer, AstraZeneca, Wilmington, DE, USA |
Sheila E. Stranks, MBA
Vice President and Deputy Compliance Officer, Shire Pharmaceuticals Group PLC, Hampshire, UK |
Brian Riewerts
Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Baltimore, MD, USA (Moderator)
|
|
|
|
SAVE THE DATE
|
FIRST ASIA PACIFIC PHARMACEUTICAL COMPLIANCE CONGRESS AND BEST PRACTICES FORUM
Sponsored by the Pharmaceutical Compliance Forum
September 13 - 15, 2011
The Ritz-Carlton, Millenia
Singapore
www.AsianPharmaCongress.com
|
|
FIRST LATIN AMERICAN PHARMACEUTICAL COMPLIANCE CONGRESS AND BEST PRACTICES FORUM
Sponsored by the Pharmaceutical Compliance Forum
2012
Panama City, Panama
www.LatinAmericanPharmaCongress.com
|
|
TWELFTH PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS
Sponsored by the Pharmaceutical Compliance Forum
November 2 - 4, 2011
Mandarin Oriental
Washington, DC
www.PharmaCongress.com
|
|
|
|
|
|
SPONSORED BY:
|
|
The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field, and sponsors a two-day international compliance congress in the Spring and a three-day US compliance congress each Fall.
|
|
|
CONGRESS CO CHAIRS
|
Gabor Danielfy
Vice-President & Global Compliance Officer, Sanofi-aventis, Paris, France
|
Kelly B. Freeman, PhD
Ethics and Compliance Officer, Eli Lilly and Company, Executive Committee Member, Pharmaceutical Compliance Forum, Indianapolis, IN, USA
|
Dominique Laymand, Esq.
Executive Director Compliance & Ethics EMEA (Europe, Middle-East, Africa, Russia and Turkey), Bristol-Myers Squibb, Paris, France
|
Roeland Van Aelst
Vice President EMEA & Canada, J&J Office Health Care Compliance & Privacy, Johnson&Johnson, Brussels, Belgium
|
|
|
GRANTORS:
|
|
DIAMOND
|
|
|
GOLD
|
|
|
BRONZE
|
|
|
MEDIA PARTNER
|
|
|
2011 INTERNATIONAL PHARMA CONGRESS PLANNING COMMITTEE
|
Kelly B. Freeman, PhD
Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN, USA (Co chair)
Dominique Laymand, Esq.
Executive Director Compliance & Ethics EMEA (Europe, Middle-East, Africa, Russia and Turkey), Bristol-Myers Squibb, Paris, France (Co chair)
Roeland Van Aelst
Vice President EMEA & Canada, J&J Office Health Care Compliance & Privacy, Johnson&Johnson, Brussels, Belgium (Co chair)
Ted Acosta, Esq.
Principal, Ernst & Young LLP, Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France
Ann Beasley Bacon
Global Compliance Officer, Novartis Pharma AG, Basel, Switzerland
Wayne Baker
Sr. Vice President, Advanced Health Media LLC, Bridgewater, NJ, USA
Karie Jo Barwind, Esq.
Area Director Business Practices, Western Europe, Abbott Laboratories, Rungis Cedex, France
Bulent Becan
Managing Partner, Atuva Management Consultancy and Trade Ltd., Consultant in Ethics Issues, Turkish Research Based Pharmaceutical Companies Association (AIFD), Istanbul, Turkey
John T. Bentivoglio, Esq.
Partner, Skadden Arps LLP, Washington, DC, USA
Gabor Danielfy
Vice-President & Global Compliance Officer, Sanofi-aventis, Paris, France
Pierre E. Dupourque
Regional Compliance Director, Corporate Compliance, International Investigations and Programs, Pfizer Inc, Mannheim, Germany
Sue Egan
Director and Principal Consultant, Sue Egan Associates, Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK
Sameh Farag
Regional Compliance Director, MEA, Merck, Dubai, United Arab Emirates
Gary F. Giampetruzzi, Esq.
Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc, New York, NY, USA
Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA
Maxine Nogard
Senior Director, Global Corporate Compliance, Biogen Idec Inc., Weston, MA, USA
Brian Riewerts
Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Baltimore, MD, USA
Jeffrey Rosenbaum
Global Head, Ethics & Compliance, Novartis Oncology, Florham Park, NJ, USA
Guillaume Roussel
Vice President, Compliance Solutions EMEA, Cegedim, Paris, France
Joseph B. Tompkins, Jr.
Partner, Sidley Austin LLP, Former Deputy Chief of the Fraud Section, Criminal Division of the United States Department of Justice, Washington, DC, USA
Paul B. Woods, BPharm, MA, MRPharmS
Global Compliance Policy Director, AstraZeneca, Macclesfield, Cheshire, UK
Elisabethann Wright, Esq.
Partner, Hogan Lovells, Former, Senior Legal Officer and Hearing Officer, EFTA Surveillance Authority, Brussels, Belgium
|
|
|
PAST INTERNATIONAL PHARMA CONGRESSES
|
2007 - Brussels, Belgium
2008 - Paris, France
2009 - Rome, Italy
2010 - Berlin, Germany
|
|
|
FOLLOW INTERNATIONAL PHARMA CONGRESS ON
|
|
|
|
|
|
|
